Temasek backs Orchard Therapeutics’ $150m Series C round

An automated machine works on purification of potential hepatitis C virus drug candidate at the Gilead Sciences Inc. lab in Foster City, California, U.S., on Wednesday, Feb. 8, 2012. Photographer: David Paul Morris/Bloomberg

Biotech firm Orchard Therapeutics has announced the completion of a $150-million Series C financing led by Deerfield Management.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.